California is currently home to 5602 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of INKmune in Patients With mCRPC (CaRe Prostate)
NCT06056791
Recruiting
This is an open-label, phase I/IIa dose escalation and expansion study of INKmune in men with mCRPC. INKmune is administered to patients intravenously over three doses, at least one-week apart. The study will consist of two stages.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: VA Greater Los Angeles Healthcare System, Los Angeles, California
Conditions: Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC
Register for Updates
A Clinical Trial of STP0404 in Adults With HIV-1 Infection
NCT05869643
Recruiting
The purpose of this study is to evaluate the antiviral effect, safety, tolerability, and pharmacokinetics of STP0404 in adult participants living with Human Immunodeficiency Virus Type 1 (HIV-1) infection.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/08/2025
Locations: Kaiser Permenente Los Angeles Medical Center, Los Angeles, California
Conditions: HIV-1-infection
Register for Updates
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
NCT05668988
Recruiting
This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD9008 versus platinum-based doublet chemotherapy in participants with locally advanced or metastatic NSCLC with EGFR Exon20ins mutation, who are newly diagnosed or have not received prior systemic therapy in advanced stage. Primary objective of this study is to assess the efficacy of DZD9008 versus platinum-based doublet chemotherapy using by BICR-assessed PFS per RECIST 1.1 as primary endpoint.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: OPN Healthcare, Inc., Glendale, California
Conditions: Non-small Cell Lung Cancer
Register for Updates
Efficacy of Trigeminal Nerve Stimulation for ADHD
NCT05374187
Recruiting
This study is a large multisite randomized clinical trial to asses the efficacy of external trigeminal nerve stimulation (TNS), a novel, minimal risk, non-invasive neuromodulation treatment, for ADHD in children ages 7-12 years old (N=180). Study hypotheses address potential differences in ADHD symptoms over 4 weeks treatment with active vs. sham TNS in an expanded multi-site investigation; whether resting state fronto-parietal connectivity mediates TNS impact on ADHD symptoms; if changes in fr... Read More
Gender:
ALL
Ages:
Between 7 years and 12 years
Trial Updated:
05/08/2025
Locations: University of California, Los Angeles, Los Angeles, California
Conditions: Attention-Deficit Hyperactivity Disorder
Register for Updates
Influence of Sun Protection and Linear Repair of Cutaneous Surgical Defects
NCT05074238
Recruiting
The purpose of this study is to determine the potential influence of sun protection on the aesthetic outcome of post-surgical scars following the reconstruction of Mohs micrographic surgery defects via linear repair. This study will be performed as a randomized split-wound study. Half of the wound will be treated with zinc containing sunscreen and the other half of the wound would not be treated. Three-months post-surgery, the scar will be evaluated via the patient observer scar assessment scale... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: University of California, Davis, Sacramento, California
Conditions: Surgical Wound, Wound Heal, Wound of Skin, Scar
Register for Updates
Cannabis Effects as a Function of Sex
NCT04385082
Recruiting
The purpose of this research is to assess the impact of cannabis on the analgesic and abuse-related effects between men and women
Gender:
ALL
Ages:
Between 21 years and 55 years
Trial Updated:
05/08/2025
Locations: University of California, Los Angeles, Los Angeles, California
Conditions: Pain, Abuse, Drug
Register for Updates
Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome
NCT03708900
Recruiting
Multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing's syndrome.
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
05/08/2025
Locations: University of California San Francisco UCSF, San Francisco, California
Conditions: Cushing Syndrome
Register for Updates
Women's Heart Attack Research Program: Stress Ancillary Study
NCT02914483
Recruiting
The Women's HARP study is a multi-center study focusing on women with clinical presentation of myocardial infarction (MI). Women will complete stress questionnaires following presentation to the medical center with elevated cardiac enzymes and abnormal electrocardiograms (ECGs). 2 months following MI, participants will be screened for the Stress Ancillary Study and enrolled if an elevated level of perceived stress is reported. After completing baseline assessments, participants will be randomize... Read More
Gender:
FEMALE
Ages:
Between 21 years and 99 years
Trial Updated:
05/08/2025
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Myocardial Infarction
Register for Updates
Natural History of Sphingosine Phosphate Lyase Insufficiency Syndrome (SPLIS)
NCT06669949
Recruiting
This is a prospective longitudinal natural history study with a retrospective cross-sectional arm aimed at determining the natural history of sphingosine phosphate lyase insufficiency syndrome (SPLIS), a recently recognized inborn error of metabolism. The central hypothesis is that age of onset, other disease features, and disease biomarkers will be predictive of quality of life (QOL) and survival in SPLIS patients.
Gender:
ALL
Ages:
All
Trial Updated:
05/07/2025
Locations: University of California San Francisco, San Francisco, California
Conditions: Sphingosine Phosphate Lyase Insufficiency Syndrome (SPLIS)
Register for Updates
Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study
NCT06651580
Recruiting
This clinical trial collects blood, saliva, urine, or stool samples to help identify possible genetic mutations that may increase a person's chance at developing pancreatic cancer. Finding genetic markers among pediatric patients with acute recurrent pancreatitis and chronic pancreatitis may help identify patients who are at risk of pancreatic cancer.
Gender:
ALL
Ages:
17 years and below
Trial Updated:
05/07/2025
Locations: Children's Hospital Los Angeles, Los Angeles, California
Conditions: Chronic Pancreatitis, Exocrine Pancreas Carcinoma, Recurrent Acute Pancreatitis
Register for Updates
DISCOVERY of Risk Factors for Type 2 Diabetes in Youth
NCT06525259
Recruiting
The goal of the DISCOVERY study is to provide innovative critical information regarding the unique natural history of glycemic control, insulin sensitivity, and β-cell function, and their mechanistic determinates, in obese adolescents at risk for developing type 2 diabetes.
Gender:
ALL
Ages:
Between 9 years and 14 years
Trial Updated:
05/07/2025
Locations: Children's Hospital Los Angeles, Los Angeles, California
Conditions: Diabetes Mellitus Type 2, Childhood-Onset
Register for Updates
A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy
NCT06388707
Recruiting
This will be a prospective, open-label, single-arm, multi-center, pilot study to evaluate the safety, tolerability, and preliminary efficacy of low-intensity focused ultrasound (LIFU) neuromodulation using NaviFUS System in patients with drug-resistant unilateral or bilateral temporal lobe epilepsy (DR-TLE).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: Stanford University School of Medicine, Palo Alto, California
Conditions: Drug Resistant Epilepsy, Epilepsy
Register for Updates